Today: 19 July 2026
MongoDB stock bounces in premarket after 6% slide; traders eye MongoDB.local and earnings clock
15 January 2026
2 mins read

MongoDB stock bounces in premarket after 6% slide; traders eye MongoDB.local and earnings clock

New York, Jan 15, 2026, 04:59 EST — Premarket

  • MongoDB climbed 1.3% in premarket trading, bouncing back from a 5.9% slide on Wednesday
  • High-growth software stocks have come under pressure as investors shift away from expensive tech
  • Later Thursday, the MongoDB.local event in San Francisco might shape the short-term outlook

Shares of MongoDB climbed 1.3% to $392.09 in early trading Thursday, clawing back some losses from the previous day. The database software company’s stock had closed 5.9% lower at $386.89 on Wednesday. Premarket trading occurs before U.S. markets open at 9:30 a.m. ET.

The stock has struggled through a volatile week. Since closing at $440.60 on Jan. 7, MongoDB has dropped roughly 12%. On Wednesday, its price swung between about $410 and $385, based on available data.

That’s significant given MongoDB has stood out among large-cap software stocks, soaring roughly 97% in the past six months and recently hitting a 52-week peak at $444.72. A retreat from that high might trigger a larger correction if investors conclude the current valuation already factors in the next growth phase.

Expensive tech stocks took a hit as the Nasdaq dropped 1% on Wednesday, Reuters noted. Investors shifted out of pricey megacaps, favoring value and defensives instead. “Investors are looking to rotate out of expensive megacaps and into value and more defensive names,” said Michael O’Rourke, chief market strategist at JonesTrading. Reuters

MongoDB takes center stage Thursday with its MongoDB.local San Francisco general session at 10 a.m. PT, per the company’s events page. Investors are likely tuning in for product updates and new customer stories that might sway sentiment following the midweek slide.

On Jan. 13, MongoDB announced that Atlas Stream Processing now supports integration with Confluent’s Schema Registry for Avro message formats, targeting teams that handle data through Kafka-like pipelines. Atlas is MongoDB’s cloud database service, and stream processing enables developers to work with data in real time rather than relying on batch jobs.

The pitch is familiar: store more of the data stack within MongoDB’s platform and simplify building real-time apps for customers. For investors, it boils down to whether Atlas usage keeps growing within enterprise budgets that remain under close scrutiny.

Analyst sentiment remains largely positive even as the stock cools off. On Jan. 12, Barclays’ Raimo Lenschow bumped his price target for MongoDB to $480 from $415, maintaining an Overweight rating, according to a note reported by TheFly. He pointed to “macro and IT spending are stable” while outlining the company’s 2026 software outlook. TipRanks

MongoDB reported third-quarter revenue of $628.3 million on Dec. 1, marking a 19% increase from the previous year. Atlas revenue jumped 30%, now representing 75% of the company’s total. The firm added roughly 2,600 customers, pushing the total beyond 62,500 by Oct. 31.

The downside is clear-cut. MongoDB’s consumption-based cloud model can slow sharply if clients cut back on usage, and with its premium valuation, there’s little margin for error. Competition remains fierce, from hyperscalers’ own database offerings to rival data platforms targeting those workloads.

The next question is whether management can leverage Thursday’s event to stabilize the story and prevent the premarket gains from slipping once the market opens. Wall Street is eyeing the next earnings report around March 4, although the company hasn’t officially set a date, per Zacks’ earnings calendar. That report — along with any updates on Atlas growth and customer spending — is the key catalyst traders are watching.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Neurocrine Biosciences (NBIX) Stock Fair Value and Performance in Focus
    July 19, 2026, 3:59 PM EDT. Neurocrine Biosciences (NBIX) is viewed as near fairly valued, with shares trading at a P/E ratio of 25.7x versus a fair value estimate of 26.0x. The stock has increased 73.4% over five years and posted a 29.4% gain in the past year, though this trails some competitors. Valuation signals are mixed, with about half indicating the stock could be expensive. Investors are assessing the resilience of cash flows from current therapies alongside operational risks. Growth prospects are supported by a broad pipeline, including late-stage assets and early commercial progress, yet policy changes and concentration risks are present. The overall assessment shows a valuation that reflects tempered expectations for Neurocrine's earnings potential and profitability.
Kohl’s stock slides 5% as Jefferies trims target to $22, tariff ruling keeps retailers on edge
Previous Story

Kohl’s stock slides 5% as Jefferies trims target to $22, tariff ruling keeps retailers on edge

Bitcoin price nears $97,000 as ETF inflows rebound and Senate crypto bill stalls
Next Story

Bitcoin price nears $97,000 as ETF inflows rebound and Senate crypto bill stalls

Go toTop